THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the presentation of detailed results of a Phase 3 study with Vectibix (panitumumab). The study met its primary endpoint, demonstrating a statistically significant improvement in overall survival in patients with chemorefractory wild-type KRAS metastatic colorectal cancer.
Amgen reported that, in the study, patients with wild-type KRAS (exon 2) mCRC treated with Vectibix and best supportive care achieved a median overall survival of 10 months compared to 7.4 months for patients treated with BSC alone.
Copyright RTT News/dpa-AFX
© 2016 AFX News
